CompletedNCT01557569
Atomoxetine or Placebo and Time to Methamphetamine Relapse
About this title
Read the official source — NCT01557569Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little RockSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- University of Arkansas
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01557569
- Official title
Show the full official title
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Arkansas, a university.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
